Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Clinical trial NCT03422393 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03422393
- Sponsor
- Michael Choi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-01
- Primary completion
- 2024-08-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.